Glioblastoma Education
Glioblastoma remains one of oncology's greatest unmet needs, with emerging immunotherapy approaches, targeted agents, and novel delivery methods offering new hope. Knowledge Med sessions help physicians stay current on this rapidly evolving field through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing glioblastoma & brain tumors face evolving treatment decisions that interactive, independently reviewed education can help address.
- Optimizing standard-of-care temozolomide-radiation based on MGMT methylation status
- Evaluating emerging immunotherapy and targeted therapy approaches for recurrent GBM
- Managing tumor treating fields (TTFields) integration and patient adherence
- Navigating the expanding clinical trial landscape for treatment-refractory disease
What Sessions Cover
Knowledge Med GBM sessions use interactive case simulations to address these topics and more.
- MGMT-stratified treatment approaches in newly diagnosed glioblastoma
- Recurrent GBM: bevacizumab, lomustine, and emerging systemic options
- Immunotherapy in brain tumors: checkpoint inhibitors, vaccines, and CAR-T
- Novel therapeutic approaches: gene therapy, oncolytic viruses, and targeted agents
Interactive GBM Sessions
Case Simulations
Work through realistic glioblastoma & brain tumors patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key GBM clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a GBM Session
Third-party, non-promotional glioblastoma & brain tumors education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session